The Company’s flagship candidate, gevokizumab (formerly XOMA 052), is a humanized allosteric monoclonal antibody to interleukin beta (IL-1β). Gevokizumab is enrolling patients in three Phase 3 non-infectious uveitis clinical trials and in two Phase 2 proof-of-concept studies for moderate to severe acne and erosive osteoarthritis of the hand. Based upon its mechanism of action, gevokizumab may also have the potential to address therapeutic needs in cardiovascular disease and other conditions associated with inflammation. XOMA is developing gevokizumab in collaboration with Les Laboratoires Servier, a leading independent pharmaceutical company.
XOMA’s preclinical pipeline includes the XMet program, which consists of three separate classes of Selective Insulin Receptor Modulators (SIRMs) antibodies: XMet A, XMet S and XMet D. XOMA is developing these antibodies to modulate the insulin receptor in a variety of ways for the potential treatment of diabetes and other metabolic syndromes.
The Company also is developing XOMA 3AB, a three-antibody co-formulation drug product candidate designed to treat botulinum toxin (Type A) poisoning, among the most deadly bioterror threats. XOMA 3AB, currently in Phase 1 testing, is being developed with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
XOMA has two product candidates that are being developed by Novartis: HCD122, a monoclonal antibody to CD40, and LFA102, a monoclonal antibody to the prolactin receptor which is currently in a Phase 1 clinical trial for certain breast and prostate cancers.